Lessons from two human chromatin diseases, ICF syndrome and Rett syndrome

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 1, 2009, Pages 117-126

  Matarazzo, M R ^a   De Bonis, M L ^a   Vacca, M ^a   Della Ragione, F ^a   D'Esposito, M ^a  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

Author keywords

Chromatin; DNA methylation; ICF syndrome; Nuclear architecture; Rett syndrome

Indexed keywords

BINDING PROTEIN; DNA METHYLTRANSFERASE;

CHROMATIN DISEASE; CHROMATIN STRUCTURE; DNA METHYLATION; EPIGENETICS; FACE MALFORMATION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNE DEFICIENCY; METHYLATION; NONHUMAN; RETT SYNDROME; REVIEW;

ABNORMALITIES, MULTIPLE; CHROMATIN; CHROMOSOME ABERRATIONS; DNA METHYLATION; FACIAL ASYMMETRY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MODELS, MOLECULAR; RETT SYNDROME; SYNDROME;

EID: 55949133391     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.07.026     Document Type: Review

References (101)

1. Agarwal N., Hardt T., Brero A., Nowak D., Rothbauer U., Becker A., et al. MeCP2 interacts with HP1 and modulates its heterochromatin association during myogenic differentiation. Nucl Acids Res 35 (2007) 5402-5408
2. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., and Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23 (1999) 185-188
3. Bebbington A., Anderson A., Ravine D., Fyfe S., Pineda M., de Klerk N., et al. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology 70 (2008) 868-875
4. Bender W., and Peifer M. Oncogenes take wing. Cell 50 (1987) 519-520
5. Bienvenu T., and Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognised. Nat Rev Genet 7 (2006) 415-426
6. Bird A.P. Gene number, noise reduction and biological complexity. Trends Genet 11 (1995) 94-100
7. Blanco-Betancourt C.E., Moncla A., Milili M., Jiang Y.L., Viegas-Pequignot E.M., Roquelaure B., et al. Defective B-cell-negative selection and terminal differentiation in the ICF syndrome. Blood 103 (2004) 2683-2690
8. Bourc'his D., Miniou P., Jeanpierre M., Molina Gomes D., Dupont J., De Saint-Basile G., et al. Abnormal methylation does not prevent X inactivation in ICF patients. Cytogenet Cell Genet 84 (1999) 245-252
9. Brero A., Easwaran H.P., Nowak D., Grunewald I., Cremer T., Leonhardt H., et al. Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. J Cell Biol 169 (2005) 733-743
10. Brown K.E., Baxter J., Graf D., Merkenschlager M., and Fisher A.G. Dynamic repositioning of genes in the nucleus of lymphocytes preparing for cell division. Mol Cell 3 (1999) 207-217
11. Chadwick L.H., and Wade P.A. MeCP2 in Rett syndrome: transcriptional repressor or chromatin architectural protein?. Curr Opin Genet Dev 17 (2007) 121-125
12. Chahrour M., and Zoghbi H.Y. The story of Rett syndrome: from clinic to neurobiology. Neuron 56 (2007) 422-437
13. Chen T., Ueda Y., Dodge J.E., Wang Z., and Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 23 (2003) 5594-5605
14. Chen W.G., Chang Q., Lin Y., Meissner A., West A.E., Griffith E.C., et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302 (2003) 885-889
15. Clouaire T., and Stancheva I. Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin?. Cell Mol Life Sci 65 (2008) 1509-1522
16. Collins A.L., Levenson J.M., Vilaythong A.P., Richman R., Armstrong D.L., Noebels J.L., et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet 13 (2004) 2679-2689
17. Colucci M., Cocito L., Capello E., Mancardi G.L., Serrati C., Cinque P., et al. Progressive multifocal leukoencephalopathy in an adult patient with ICF syndrome. J Neurol Sci 217 (2004) 107-110
18. Colvin L., Fyfe S., Leonard S., Schiavello T., Ellaway C., de Klerk N., et al. Describing the phenotype in Rett syndrome using a population database. Arch Dis Child 88 (2003) 38-43
19. Couvert P., Bienvenu T., Aquaviva C., Poirier K., Moraine C., Gendrot C., et al. MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 10 (2001) 941-946
20. De Bona C., Zappella M., Hayek G., Meloni I., Vitelli F., Bruttini M., et al. Preserved speech variant is allelic of classic Rett syndrome. Eur J Hum Genet 8 (2000) 325-330
21. D'Esposito M., Quaderi N.A., Ciccodicola A., Bruni P., Esposito T., D'Urso M., et al. Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm Genome 7 (1996) 533-535
22. Ehrlich M. The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin Immunol 109 (2003) 17-28
23. Ehrlich M., Buchanan K.L., Tsien F., Jiang G., Sun B., Uicker W., et al. DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes. Hum Mol Genet 10 (2001) 2917-2931
24. Ehrlich M., Jackson K., and Weemaes C. Immunodeficiency, centromeric region instability, facial anomalies syndrome (ICF). Orphanet J Rare Dis 1 (2006) 2
25. Ehrlich M., Sanchez C., Shao C., Nishiyama R., Kehrl J., Kuick R., et al. ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 41 (2008) 253-271
26. Gennery A.R., Slatter M.A., Bredius R.G., Hagleitner M.M., Weemaes C., Cant A.J., et al. Hematopoietic stem cell transplantation corrects the immunologic abnormalities associated with immunodeficiency-centromeric instability-facial dysmorphism syndrome. Pediatrics 120 (2007) e1341-1344
27. Giacometti E., Luikenhuis S., Beard C., and Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci USA 104 (2007) 1931-1936
28. Gibbons R.J., Bachoo S., Picketts D.J., Aftimos S., Asenbauer B., Bergoffen J., et al. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. Nat Genet 17 (1997) 146-148
29. Girard M., Couvert P., Carrie A., Tardieu M., Chelly J., Beldjord C., et al. Parental origin of de novo MECP2 mutations in Rett syndrome. Eur J Hum Genet 9 (2001) 231-236
30. Gisselsson D., Shao C., Tuck-Muller C.M., Sogorovic S., Palsson E., Smeets D., et al. Interphase chromosomal abnormalities and mitotic missegregation of hypomethylated sequences in ICF syndrome cells. Chromosoma 114 (2005) 118-126
31. Goll M.G., and Bestor T.H. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 74 (2005) 481-514
32. Goll M.G., Kirpekar F., Maggert K.A., Yoder J.A., Hsieh C.L., Zhang X., et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 311 (2006) 395-398
33. Gowher H., and Jeltsch A. Molecular enzymology of the catalytic domains of the Dnmt3a and Dnmt3b DNA methyltransferases. J Biol Chem 277 (2002) 20409-20414
34. Guy J., Gan J., Selfridge J., Cobb S., and Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315 (2007) 1143-1147
35. Guy J., Hendrich B., Holmes M., Martin J.E., and Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27 (2001) 322-326
36. Hagberg B., Dias A.J., and Ramos K.O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 4 (1983) 471-479
37. Hansen R.S., Stöger R., Wijmenga C., Vary J.C., Stanek A.M., Canfield T.K., et al. Escape from gene silencing in ICF syndrome and evidence for advanced replication time as a major determinant. Hum Mol Genet 9 (2000) 2575-2587
38. Hansen R.S., Wijmenga C., Luo P., Stanek A.M., Canfield T.K., Weemaes C.M., et al. The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc Natl Acad Sci USA 96 (1999) 14412-14417
39. Hata K., Okano M., Lei H., and Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 129 (2002) 1983-1993
40. Hernandez R., Frady A., Zhang X.Y., Varela M., and Ehrlich M. Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine. Cytogenet Cell Genet 76 (1997) 196-201
41. Horike S., Cai S., Miyano M., Cheng J.F., and Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet 37 (2005) 31-40
42. Ishii T., Makita Y., Ogawa A., Amamiya S., Yamamoto M., Miyamoto A., et al. The role of different X-inactivation pattern on the variable clinical phenotype with Rett syndrome. Brain Dev 23 Suppl. 1 (2001) S161-164
43. Jeanpierre M., Turleau C., Aurias A., Prieur M., Ledeist F., Fischer A., et al. An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Hum Mol Genet 2 (1993) 731-735
44. Jiang Y.L., Rigolet M., Bourc'his D., Nigon F., Bokesoy I., Fryns J.P., et al. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum Mutat 25 (2005) 56-63
45. Jin B., Tao Q., Peng J., Soo H.M., Wu W., Ying J., et al. DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis, and immune function. Hum Mol Genet 17 (2008) 690-709
46. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19 (1998) 187-191
47. Jugloff D.G., Vandamme K., Logan R., Visanji N.P., Brotchie J.M., and Eubanks J.H. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum Mol Genet 17 (2008) 1386-1396
48. Kaufmann W.E., Jarrar M.H., Wang J.S., Lee Y.J., Reddy S., Bibat G., et al. Histone modifications in Rett syndrome lymphocytes: a preliminary evaluation. Brain Dev 27 (2005) 331-339
49. Kerr A.M. Rett syndrome British Longitudinal Study (1982-1990) and 1990 survey. In: Rosendaal J.J. (Ed). Mental retardation and medical care, April 21-24 (1991), Uitgeverij Kerckbosch, Zeist 143-145
50. Kerr A.M., Nomura Y., Armstrong D., Anvret M., Belichenko P.V., Budden S., et al. Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev 23 (2001) 208-211
51. Klein M.E., Lioy D.T., Ma L., Impey S., Mandel G., and Goodman R.H. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Nat Neurosci 10 (2007) 1513-1514
52. Kriaucionis S., and Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucl Acids Res 32 (2004) 1818-1823
53. Kriaucionis S., Paterson A., Curtis J., Guy J., Macleod N., and Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol 26 (2006) 5033-5042
54. Kubota T., Furuumi H., Kamoda T., Iwasaki N., Tobita N., Fujiwara N., et al. ICF syndrome in a girl with DNA hypomethylation but without detectable DNMT3B mutation. Am J Med Genet A 129 (2004) 290-293
55. Kudo S., Nomura Y., Segawa M., Fujita N., Nakao M., Schanen C., et al. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J Med Genet 40 (2003) 487-493
56. Mari F., Azimonti S., Bertani I., Bolognese F., Colombo E., Caselli R., et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early seizure variant of Rett syndrome. Hum Mol Genet 14 (2005) 1935-1946
57. Martinowich K., Hattori D., Wu H., Fouse S., He F., Hu Y., et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302 (2003) 890-893
58. Matarazzo M.R., Boyle S., D'Esposito M., and Bickmore W.A. Chromosome territory reorganization in a human disease with altered DNA methylation. Proc Natl Acad Sci USA 104 (2007) 16546-16551
59. Matarazzo M.R., De Bonis M.L., Gregory R.I., Vacca M., Hansen R.S., Mercadante G., et al. Allelic inactivation of the pseudoautosomal gene SYBL1 is controlled by epigenetic mechanisms common to the X and Y chromosomes. Hum Mol Genet 11 (2002) 3191-3198
60. Matarazzo M.R., De Bonis M.L., Strazzullo M., Cerase A., Ferraro M., Vastarelli P., et al. Multiple binding of methyl-CpG and Polycomb proteins in long-term gene silencing events. J Cell Physiol 210 (2007) 711-719
61. Miniou P., Jeanpierre M., Blanquet V., Sibella V., Bonneau D., Herbelin C., et al. Abnormal methylation pattern in constitutive and facultative (X inactive chromosome) heterochromatin of ICF patients. Hum Mol Genet 3 (1994) 2093-2102
62. Mnatzakanian G.N., Lohi H., Munteanu I., Alfred S.E., Yamada T., MacLeod P.J., et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Genet 36 (2004) 339-341
63. Nakagawa T., Kanai Y., Ushijima S., Kitamura T., Kakizoe T., and Hirohashi S. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. J Urol 173 (2005) 243-246
64. Nan X., Hou J., Maclean A., Nasir J., Lafuente M.J., Shu X., et al. Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc Natl Acad Sci USA 104 (2007) 2709-2714
65. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393 (1998) 386-389
66. Nomura T., Kimura M., Horii T., Morita S., Soejima H., Kudo S., et al. MeCP2-dependent repression of an imprinted miR-184 released by depolarisation. Hum Mol Genet 17 (2008) 1192-1199
67. Ogier M., Wang H., Hong E., Wang Q., Greenberg M.E., and Katz D.M. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci 27 (2007) 10912-10917
68. Okano M., Bell D.W., Haber D.A., and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999) 247-257
69. Perini G., and Tupler R. Altered gene silencing and human diseases. Clin Genet 69 (2006) 1-7
70. Philippe C., Villard L., De Roux N., Raynaud M., Bonnefond J.P., Pasquier L., et al. Spectrum and distribution of MECP2 mutations in 424 Rett syndrome patients: a molecular update. Eur J Med Genet 49 (2006) 9-18
71. Renieri A., Meloni I., Longo I., Ariani F., Mari F., Pescucci C., et al. Rett syndrome: the complex nature of a monogenic disease. J Mol Med 81 (2003) 346-354
72. Rett A. Über ein eigenartiges hirnatrophisches Syndrom bei Hyperammonemie im Kindesalter. Wien Med Wochenschr 116 (1966) 723-728
73. Roux J.C., Dura E., Moncla A., Mancini J., and Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci 25 (2007) 1915-1922
74. Sabbattini P., Lundgren M., Georgiou A., Chow C., Warnes G., and Dillon N. Binding of Ikaros to the lambda5 promoter silences transcription through a mechanism that does not require heterochromatin formation. EMBO J 20 (2001) 2812-2822
75. Samaco R.C., Fryer J.D., Ren J., Fyffe S., Chao H.T., Sun Y., et al. A partial loss of function allele of methyl-CpG-binding protein predicts a human neurodevelopmental syndrome. Hum Mol Genet 17 (2008) 1718-1727
76. Scala E., Longo I., Ottimo F., Speciale C., Sampieri K., Katzaki E., et al. MECP2 deletions and genotype-phenotype correlation in Rett syndrome. Am J Med Genet A 143 (2007) 2775-2784
77. Scarano M.I., Strazzullo M., Matarazzo M.R., and D'Esposito M. DNA methylation 40 years later: its role in human health and disease. J Cell Physiol 204 (2005) 21-35
78. Schuetz C., Barbi G., Barth T.F., Hoenig M., Schulz A., Moeller P., et al. ICF syndrome: high variability of the chromosomal phenotype and association with classical Hodgkin lymphoma. Am J Med Genet A 143 (2007) 2052-2057
79. Schule B., Li H.H., Fisch-Kohl C., Purmann C., and Francke U. DLX5 and DLX6 expression is biallelic and not modulated by MeCP2 deficiency. Am J Hum Genet 81 (2007) 492-506
80. Shahbazian M., Young J., Yuva-Paylor L., Spencer C., Antalffy B., Noebels J., et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35 (2002) 243-254
81. Shirohzu H., Kubota T., Kumazawa A., Sado T., Chijiwa T., Inagaki K., et al. Three novel DNMT3B mutations in Japanese patients with ICF syndrome. Am J Med Genet 112 (2002) 31-37
82. Smeets D.F., Moog U., Weemaes C.M., Vaes-Peeters G., Merkx G.F., Niehof J.P., et al. ICF syndrome: a new case and review of the literature. Hum Genet 94 (1994) 240-246
83. Thatcher K.N., and LaSalle J.M. Dynamic changes in histone H3 lysine 9 acetylation localization patterns during neuronal maturation require MeCP2. Epigenetics 1 (2006) 24-31
84. Thomas G.H. High male:female ratio of germ-line mutations: an alternative explanation for postulated gestational lethality in males in X-linked dominant disorders. Am J Hum Genet 58 (1996) 1364-1368
85. Trappe R., Laccone F., Cobilanschi J., Meins M., Huppke P., Hanefeld F., et al. MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 68 (2001) 1093-1101
86. Tudor M., Akbarian S., Chen R.Z., and Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci USA 99 (2002) 15536-15541
87. Ueda Y., Okano M., Williams C., Chen T., Georgopoulos K., and Li E. Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome. Development 133 (2006) 1183-1192
88. Urdinguio R.G., Pino I., Ropero S., Fraga M.F., and Esteller M. Histone H3 and H4 modification profiles in a Rett syndrome mouse model. Epigenetics 2 (2007) 11-14
89. Vacca M., Filippini F., Budillon A., Rossi V., Della Ragione F., De Bonis M.L., et al. MECP2 gene mutation analysis in the British and Italian Rett syndrome patients: hot spot map of the most recurrent mutations and bioinformatic analysis of a new MECP2 conserved region. Brain Dev 23 Suppl. 1 (2001) S246-250
90. Vacca M., Filippini F., Budillon A., Rossi V., Mercadante G., Manzati E., et al. Mutation analysis of the MECP2 gene in British and Italian Rett syndrome females. J Mol Med 78 (2001) 648-655
91. Van Esch H., Bauters M., Ignatius J., Jansen M., Raynaud M., Hollanders K., et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 77 (2005) 442-453
92. Viemari J.C., Roux J.C., Tryba A.K., Saywell V., Burnet H., Pena F., et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25 (2005) 11521-11530
93. Vo N., Klein M.E., Varlamova O., Keller D.M., Yamamoto T., Goodman R.H., et al. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA 102 (2005) 16426-16431
94. Wan M., Zhao K., Lee S.S., and Francke U. MECP2 truncating mutations cause histone H4 hyperacetylation in Rett syndrome. Hum Mol Genet 10 (2001) 1085-1092
95. Wang H., Chan S.A., Ogier M., Hellard D., Wang Q., Smith C., et al. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J Neurosci 26 (2006) 10911-10915
96. Wijmenga C., Hansen R.S., Gimelli G., Bjorck E.J., Davies E.G., Valentine D., et al. Genetic variation in ICF syndrome: evidence for genetic heterogeneity. Hum Mutat 16 (2000) 509-517
97. Wong N., Lam W.C., Lai P.B., Pang E., Lau W.Y., and Johnson P.J. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol 159 (2001) 465-471
98. Xie Z.H., Huang Y.N., Chen Z.X., Riggs A.D., Ding J.P., Gowher H., et al. Mutations in DNA methyltransferase DNMT3B in ICF syndrome affect its regulation by DNMT3L. Hum Mol Genet 15 (2006) 1375-1385
99. Xu G.L., Bestor T.H., Bourc'his D., Hsieh C.L., Tommerup N., Bugge M., et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402 (1999) 187-191
100. Yasui D.H., Peddada S., Bieda M.C., Vallero R.O., Hogart A., Nagarajan R.P., et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci USA 104 (2007) 19416-19421
101. Zhou Z., Hong E.J., Cohen S., Zhao W.N., Ho H.Y., Schmidt L., et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52 (2006) 255-269